Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy

The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck

“…Recent clinical data from studies utilizing gene therapy for the treatment of cancer have shown promising results, particularly those strategies utilizing either adenoviral delivered wild-type p53 or replication-competent adenoviruses [11][12][13][14]. Adenoviruses are double-stranded DNA viruses that are widely used as vectors for gene therapy due to their superior ability to transfer genes in vivo, as well as their broad tissue tropism [15].…”

Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas

“…Combined modality therapy, most frequently radiosensitizing chemotherapy and radiation, have been shown to be particularly efficient and have become standard therapy for many tumor types. 28 One of the most promising therapies that can be combined with ionizing radiation in the treatment of prostate cancer is gene therapy. Several biological sKDR inhibits human prostate cancer cell growth SA Kaliberov et al features of the prostate make it an attractive target for the development of gene therapy strategies in combination with radiotherapy for treatment of localized prostate cancer.…”

“…This circumstance provides a degree of greater latitude in the gene therapy specificity that may not be appropriate for other tumor types. 28 The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support and stimulates new tumor blood vessel growth. HUVECs were infected with 100 MOI AdVEGF-sKDR or AdCMV-Luc and after 24 h cells were irradiated at 3 Gy and immediately, 50 ng/ml of hrVEGF was added to the culture media.…”

Options thérapeutiques

“…La thérapie génique émerge comme un adjuvant prometteur aux stratégies conventionnelles, et de nombreux essais cliniques ont été eff ectués (Steiner et Gingrich 2000 ;Mabjeesh et al 2002 ;Collins et al 2003 ;Foley et al 2004 ;Mazhar et Waxman 2004).…”

“…L'immunothérapie peut être indiquée dans un contexte de maladie résiduelle minime plutôt qu'en cas de grosse tumeur. Le facteur stimulant les colonies de granulocytes-macrophages (GM-CSF), l'interleukine-2 (IL-2), IL-12, le facteur de nécrose tumorale α (tumor necrosis factor-alpha, TNF-α) et l'interféron gamma (IFN-γ) ont émergé en tant que gènes de cytokines ayant une importante effi cacité d'induction d'une réponse immunitaire anti-tumorale (Steiner et Gingrich 2000 ;Mabjeesh et al 2002 ;Collins et al 2003 ;Mazhar et Waxman 2004). Il existe 3 voies d'immunothérapie : l'injection intratumorale directe de gènes de cytokines, le traitement par vaccin génique et l'immunothérapie adoptive.…”